Autolus Therapeutics plc

AUTL · Nasdaq · United Kingdom

Share price · AUTL

$1.06-1.23 (-53.71%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.6M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AUTL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026-6.4%
  2. 11 Aug 2026+12.6%
  3. 3 Aug 2026+22.1%
  4. 23 Jun 2026+11.4%

    Nothing announced by AUTL that day or the session before.

  5. 3 Jun 2026-7.4%
  6. 19 May 2026-9.4%

    Nothing announced by AUTL that day or the session before.

  7. 18 May 2026+10.4%

    Nothing announced by AUTL that day or the session before.

  8. 16 Apr 2026+8.1%
  9. 8 Apr 2026+9.6%
  10. 12 Jan 2026-17.1%

Share of unusual movement by asset

For each asset, the share of AUTL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
obecabtagene autoleucel (Aucatzyl)
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—27%
Sessions with no dated event—72%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
CD19Cell therapy
Acute Lymphoblastic Leukemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
August 2028 (1)
Est. primary completion 2028-08 · NCT07053800 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
obecabtagene autoleucel · AucatzylPhase 1/2Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Est. primary completion 2029-06-30 · NCT04404660 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$41M$31M$247M+ $3.0M short-term inv.$55M-$19M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$46M$28M$173M+ $30M short-term inv.$39M-$25M operating cash flowreport ↗
2026-Q1$26M$21M$132M+ $99M short-term inv.$72M-$65M operating cash flowreport ↗
2025-Q3$21M$28M$88M+ $281M short-term inv.$79M-$68M operating cash flowreport ↗
2025-Q2$21M$27M$125M+ $330M short-term inv.$48M-$73M operating cash flowreport ↗
2025-Q1$9.0M$27M$97M+ $421M short-term inv.$70M-$76M operating cash flowreport ↗
2024-Q3$0$40M$659M$82M-$77M operating cash flowreport ↗
2024-Q2$0$37M$707M$58M-$51M operating cash flowreport ↗
2024-Q1—$31M$760M$53M-$41M operating cash flowreport ↗
2023-Q3—$37M$257M$46M-$40M operating cash flowreport ↗
2023-Q2—$33M$308M$46M-$38M operating cash flowreport ↗
2023-Q1—$27M$343M$40M-$42M operating cash flowreport ↗
2022-Q3—$38M$163M$43Mreport ↗
2022-Q2—$31M—$42Mreport ↗
2022-Q1—$28M—$37Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$75M$118M$106M+ $197M short-term inv.$72M-$284M operating cash flowreport ↗

For the full year 2025, Autolus reported revenue of $75.39M, up 645.0% YoY, with AUCATZYL net product revenue of $74.3M for the year. R&D spend was $117.69M, down 15.0% YoY, and cash and equivalents stood at $105.64M. The company posted a net loss of $287.53M and a quarterly net burn of $287.53M.

Management guided to 2026 AUCATZYL net product revenue of $120M to $135M and expects a shift to positive gross margin in 2026, with current cash expected to fund operations into Q4 2027. AUCATZYL launched in the UK after a successful NICE evaluation, and real-world ROCCA data confirmed consistent efficacy and safety. Key pipeline progress included enrollment in the pivotal Phase 2 CATULUS trial in pediatric r/r B-ALL and the LUMINA trial in lupus nephritis, with initial BOBCAT data in progressive MS and ALARIC data in AL amyloidosis expected by year-end 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$10M$138M$229M+ $361M short-term inv.$55M-$206M operating cash flowreport ↗
2023-FY—$130M$240M+ $0 short-term inv.$52M-$146M operating cash flowreport ↗
2022-FY—$142M$383M$37M-$112M operating cash flowreport ↗
2021-FY—$135M$311M$36M-$118M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($16K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-02Piccina Cintia · U.S. CCO & Country Gen ManagerOpen-market sale6,713$2.34$16KForm 4
2026-09-01Piccina Cintia · U.S. CCO & Country Gen ManagerOption exercise20,000$2.35$47KForm 4
2026-09-01Piccina Cintia · U.S. CCO & Country Gen ManagerOption exercise (derivative)20,000——Form 4
2026-06-29BONNEY MICHAEL W · directorAward / grant (derivative)31,667——Form 4
2026-06-29Azelby Robert · directorAward / grant (derivative)31,667——Form 4
2026-06-29Bain Linda · directorAward / grant (derivative)31,667——Form 4
2026-06-29BUTITTA CYNTHIA M · directorAward / grant (derivative)31,667——Form 4
2026-06-29Iannone Robert · directorAward / grant (derivative)31,667——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 84 reporting institutions held 134.4M shares ($184.2M, 50.5% of shares outstanding).

#InstitutionSharesValue
1MAK CAPITAL ONE LLC33,621,487$46.4M
2Blackstone Inc.20,485,611$28.3M
3Syncona Portfolio Ltd16,640,720$23.0M
4ARMISTICE CAPITAL, LLC15,800,000$21.8M
5Tetragon Partners GP Ltd9,500,000$13.1M
6SCHRODER INVESTMENT MANAGEMENT GROUP9,489,345$12.1M
7Frazier Life Sciences Management, L.P.4,447,910$6.1M
8BNP PARIBAS ASSET MANAGEMENT Holding S.A.3,361,156$4.6M
9Laurion Capital Management LP3,316,626$4.6M
10RENAISSANCE TECHNOLOGIES LLC2,299,499$3.2M
11BANK OF AMERICA CORP /DE/1,844,671$2.5M
12BlackRock, Inc.1,480,732$2.0M
13UBS Group AG1,305,779$1.8M
14Cetera Investment Advisers1,129,074$1.6M
15Balyasny Asset Management L.P.971,691$1.3M